^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYNK-101

    i
    Company:
    Celularity
    Drug class:
    NK cell stimulant
    Related drugs:
    Apply
    CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (NCT05207722)
    Phase 1/2
    Celularity Incorporated
    Active, not recruiting
    Last update posted :
    02/16/2023
    Initiation :
    04/14/2022
    Primary completion :
    02/15/2023
    Completion :
    02/15/2025
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cyclophosphamide • CYNK-101 • fludarabine IV • mesna • Proleukin (aldesleukin)